Conditions: Acute Coronary Syndrome
Keywords: phase1 healthy subjects antiplatelet agent
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 113
Healthy volunteers: yes

Brief summary:
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics. Adverse events, physical examinations, vital signs, ECG and laboratory tests will be conducted for safety/tolerability evaluation and serial blood samples and urine collections for pharmacokinetic and pharmacodynamic evaluations will be conducted at specified time points.

Detailed description:

Arms:
arm 1: experimental drug arm 2: LC23-1306 placebo arm 3: active comparator

Interventions: intervention 1: LC23-1306 intervention 2: placebo intervention 3: Ticagrelor
Intervention descriptions: intervention 1: LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg intervention 2: LC23-1306 placebo intervention 3: Ticagrelor 90mg

Protocol document: